Biotricity, Inc. (BTCY) Q3 2026 Earnings Call Transcript
Biotricity (OTCMKTS:BTCY - Get Free Report) and 111 (NASDAQ: YI - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation. Analyst Ratings This is a breakdown of recent ratings
Three Healthcare IT stocks have surged over 20% in 2025, driven by growth in telehealth, remote monitoring and value-based care platforms.
Biotricity, Inc. (OTC:BTCY) Q2 2026 Earnings Call November 14, 2025 4:30 PM EST Company Participants Waqaas Al-Siddiq - Founder, President, CEO & Chairman S. Ayanoglou - Chief Financial Officer Presentation Operator Good afternoon, and welcome to Biotricity's Second Quarter Fiscal 2026 Financial Results and Business Update Conference Call.
Biotricity Inc. (BTCY) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.07 per share a year ago.
Here is how Biotricity Inc. (BTCY) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
Biotricity (BTCY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Biotricity, Inc. (OTC:BTCY) Q4 2025 Earnings Call July 18, 2025 4:45 PM ET Company Participants S. John Ayanoglou - Chief Financial Officer Waqaas Al-Siddiq - Founder, President, CEO & Chairman Conference Call Participants Michael John Donovan - H.C.
Purpose Bitcoin Yield ETF offers monthly distributions and long-term capital appreciation through holding Bitcoin and a covered call strategy. The ETF generates a 12.07% yield over a rolling 12-month period. Eligible for TFSAs and RRSPs, the ETF offers potential tax benefits, making it an attractive option for tax-efficient investment growth.
Biotricity, Inc. (OTC:BTCY) Q2 2025 Earnings Conference Call November 15, 2024 4:30 PM ET Company Participants Dr. Waqaas Al-Siddiq - Founder and CEO John Ayanoglou - Chief Financial Officer Conference Call Participants Kevin Dede - H.C. Wainwright Operator Greetings.
The company has achieved EBIDTA positive on a go-forward cash basis REDWOOD CITY, CA / ACCESSWIRE / October 3, 2024 / Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company that is reshaping the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today reports compelling financial and strategic advancements that will propel the company towards profitability by the end of Fiscal Q4. Biotricity is now on an accelerated trajectory to profitability due to growing revenues from sales and strategic partnerships, improving margins, and an earlier than expected milestone of achieving EBITDA positive on a go-forward cash basis.
REDWOOD CITY, CA / ACCESSWIRE / September 26, 2024 / Biotricity Inc. (OTCQB:BTCY), a leading Technology-as-a-Service (TaaS) company that is redefining the healthcare industry with cutting-edge remote monitoring and diagnostic solutions, announces its inclusion as a supplier to another major medical system that encompasses 60,000 care providers over 400 hospitals and 400 care centers. In the U.S. today, 121.5 million adults have some form of cardiovascular disease.